Advertisement

Topics

C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.

05:25 EDT 12 May 2019 | Synbiobeta

Shares of the combined company to commence trading on the NYSE American exchange under the new symbol “ARMP” on May 10, 2019 Completed $10 million concurrent financing Ongoing collaboration with Merck to develop proprietary synthetic phage candidates MARINA DEL REY, Calif., May 9, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage biotechnology […]

The post C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc. appeared first on SynBioBeta.

Original Article: C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.

NEXT ARTICLE

More From BioPortfolio on "C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...